4. Other

(1) Significant changes in subsidiaries during period (changes in specified subsidiaries involving change in consolidation scope): No

(2) Changes in accounting principles, procedures, method of presentation associated with preparation of the consolidate financial statements (matters to be included in the section, *Changes in Basic Important Matters for Preparation of Consolidated Financial Statements*)
1) Changes due to revisions of accounting standards etc.: Yes
2) Changes other than 1): Yes
(Note) Refer to *Changes in Basic Important Matters for Preparation of Consolidated Financial Statements*, on page 29, for details.

(3) Number of shares outstanding (common stock)
1) Number of shares outstanding at term end (including treasury stock):
March 31, 2008 889,272,395 shares
March 31, 2007 889,272,395 shares
2) Number of shares of treasury stock at term end
March 31, 2008 46,411,249 shares
March 31, 2007 29,895,405 shares
(Note) Refer to *Per Share Information*, on page 40, for number of shares that forms basis for calculating earnings per share.

(Reference) Summary of Unconsolidated Results

Summary of Unconsolidated Results for Fiscal 2007 (April 1, 2007 – March 31, 2008)

(1) Unconsolidated Sales and Income

(Percentage figures represent changes from same period of previous year)

	Net sales (¥ million)	Year-on-year change (%)	Operating income (¥ million)	Year-on-year change (%)	Ordinary income (¥ million)	Year-on-year change (%)
Fiscal 2007	892,546	2.7	267,935	(22.9)	272,627	(27.9)
Fiscal 2006	869,068	3.4	347,652	0.5	378,377	3.8

	Net income (¥ million)	Year-on-year change (%)	Earnings per share (¥)	Fully diluted earnings per share (¥)
Fiscal 2007	174,586	(20.6)	205.76	—
Fiscal 2006	219,813	(11.8)	252.12	—

(2) Unconsolidated Financial Position

	Total assets (¥ million)	Net assets (¥ million)	Shareholders' equity ratio (%)	Shareholders' equity per share (¥)
Fiscal 2007	1,831,704	1,526,556	83.3	1,810.98
Fiscal 2006	2,045,317	1,655,400	80.9	1,926.09

(Reference) Shareholders' equity Fiscal 2007 ¥1,526,556 million
Fiscal 2006 ¥1,655,400 million

* Note to ensure appropriate use of forecasts
The outlook presented in this presentation is the result of management's assessment based upon currently available information, and the actual performance could be influenced by various risks and uncertainties. Regarding the acquisition of Millennium Pharmaceuticals, Inc., the impacts of the acquisition are reflected with the assumption that it would become Takeda's wholly owned subsidiary. In addition, the accounting procedures and its impact on our outlook of financial statements derived from consolidation of Millennium and TAP Pharmaceutical, Inc. are based on currently available information and are not yet final.
Furthermore, the forecasted effects on consolidated results of making both TAP and Millennium wholly owned subsidiaries are for 11 months only (from May 2008 to March 2009).
For further details, please refer to "1. Results of Operations (1) Analysis of Operation Results 5) Outlook for Fiscal 2008" on page 10.